New hope for Platinum-Resistant ovarian cancer?

NCT ID NCT07278336

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 4 times

Summary

This early-stage trial tests an investigational drug called ABBV-901, alone or with a standard drug bevacizumab, in about 219 adults with advanced ovarian cancer that no longer responds to platinum chemotherapy. The main goals are to check safety and see if the drug can shrink tumors. Participants will receive the drug through an IV and will be closely monitored with frequent tests and scans over about 3 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABBV-901 (an investigational drug) and bevacizumab (a standard cancer therapy)
What this could lead to: If successful, this could point toward a new treatment option for ovarian cancer that is resistant to platinum-based therapies.
What could go wrong: This is an early Phase 1 trial, so safety and effectiveness are not yet proven. The drug may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube serous adenocarcinoma ovarian cancer ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center /ID# 282600
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200032, China
Hadassah Medical Center-Hebrew University /ID# 278420
RECRUITING

Jerusalem, 91120, Israel
NEXT Oncology - San Antonio /ID# 278606
RECRUITING

San Antonio, Texas, 78229, United States
National Cancer Center Hospital East /ID# 278604
RECRUITING

Kashiwa-shi, Chiba, 277-8577, Japan
New Zealand Clinical Research (Christchurch) /ID# 281467
NOT_YET_RECRUITING

Christchurch, Canterbury, 8011, New Zealand
Next Virginia /ID# 278607
RECRUITING

Fairfax, Virginia, 22031, United States
Qilu Hospital Of Shandong University /ID# 283564
NOT_YET_RECRUITING

Jinan, Shandong, 250014, China
Rambam Health Care Campus /ID# 278418
RECRUITING

Haifa, 3109601, Israel
Saitama Medical University International Medical Center /ID# 278437
RECRUITING

Hidaka, Saitama, 350-1298, Japan
Sarah Cannon Research Institute at HealthONE /ID# 278785
RECRUITING

Denver, Colorado, 80218, United States
Shandong Cancer Hospital /ID# 283566
NOT_YET_RECRUITING

Jinan, Shandong, 250117, China
Shizuoka Cancer Center /ID# 278538
RECRUITING

Sunto-gun, Shizuoka, 411-8777, Japan
Start Mountain Region /ID# 278609
RECRUITING

West Valley City, Utah, 84119, United States
Sun Yat-Sen University Cancer Center /ID# 282505
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510060, China
Taipei Veterans General Hospital /ID# 281349
RECRUITING

Taipei, 112, Taiwan
The Chaim Sheba Medical Center /ID# 278416
RECRUITING

Ramat Gan, Tel Aviv, 5265601, Israel
University of Chicago Medical Center /ID# 278295
RECRUITING

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.